Segmed
-62%
est. 2Y upside i
Real-World Data for Health Innovation
Rank
#659
Sector
Healthcare AI Data Platform
Est. Liquidity
~4Y
Data Quality
Data: MediumSegmed presents a strong upside opportunity for a job seeker, with an estimated 105% expected return over a two-year horizon.
Last updated: March 10, 2026
Segmed expands its network of healthcare partners significantly, becoming the dominant platform for regulatory-grade medical imaging data. Strategic partnerships with Verily and Bayer translate into substantial revenue growth, reaching $70M+ by 2028. This market leadership and strong growth justify a $600M+ valuation, representing a 5x return on current valuation.
Segmed continues its steady growth, securing additional partnerships and expanding its dataset offerings. It maintains its competitive position against niche players but faces ongoing competition from larger incumbents. Revenue grows to ~$30M by 2028, leading to an estimated valuation of $210M, providing a solid 1.75x return.
Dominant healthcare IT incumbents or cloud providers launch more aggressive, competing data platforms, or a major regulatory shift creates new hurdles. Segmed struggles to accelerate customer acquisition beyond its core network, leading to slower-than-expected revenue growth of ~$10M-$12M. Valuation compresses to $30M, wiping out most common stock value given the $20M in liquidation preferences.
Preference Stack Risk
highInvestors hold $20M in liquidation preferences, meaning common shareholders would only see returns after this amount is paid out in an exit.
Dilution Risk
moderateAs a Series A company, Segmed is likely to raise additional funding rounds (Series B, C) before a liquidity event, which will lead to further dilution of common stock.
Secondary Liquidity
noneGiven its Series A stage and ~45 employees, there is currently no active secondary market or tender offer for Segmed's equity.
Questions to Ask at the Interview
Strategic questions based on Segmed's data — designed to show you've done your homework.
- 1
“Given the partnerships with large entities like Verily and Bayer, how does Segmed balance collaboration with the potential for these partners to become competitors in the long run?”
- 2
“With ~$7M in revenue and a rapidly growing market, what are the key strategic initiatives to accelerate market penetration and scale revenue to $50M+ within the next 2-3 years?”
- 3
“Considering the Series A funding and the typical venture capital lifecycle, what is the company's anticipated timeline and strategy for a liquidity event for employees?”
Community
Valuation Sentiment
Our model estimates -62% upside. What do you think?
Anonymous. Do not share material non-public information.
Community Discussion
Comments are reviewed before they appear publicly.
Loading comments...
Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.